We are pleased to announce that Theo Hoofwijk, MD, has joined Evidera as Vice President and General Manager, Peri- and Post-Approval Interventional Studies. Under Dr. Hoofwijk’s leadership the Interventional Studies team will focus on providing optimized study design strategies and streamlined study delivery, applying learnings from real-world insights. Dr. Hoofwijk brings more than 20 years of experience working within CROs and the pharmaceutical industry, including a wealth of experience in drug safety, clinical drug development, and medical affairs research in both local country operations and the corporate pharma environment.
“We are excited to have Theo join Evidera. His extensive experience and leadership abilities will help us to expand our interventional studies capabilities and better position us to help our clients bring treatments to patients faster and more efficiently,” remarked Dr. Radek Wasiak, Vice President and Global Head of Peri- and Post-Approval Studies.
Prior to joining Evidera, Dr. Hoofwijk held a variety of positions at IQVIA, including: global medical head cardiovascular/metabolic, therapeutic strategy lead, regional chief medical officer EMEA, and head of strategic drug development APAC. During his career, he led strategic drug development activities for pharma customers and managed global programs in the cardiovascular and gastroenterology therapeutic areas. His contributions to the field include developing, leading, and supporting clinical development programs in functional bowel diseases, dyslipidemia, acute coronary syndromes, coronary artery disease, heart failure, hypertension, type 2 diabetes mellitus, and orthotopic liver transplantation.
“I am proud to join Evidera and have a role in contributing to the growth and direction of its interventional studies offerings,” remarked Dr. Hoofwijk. “By bringing together clinical evidence and real-world insights we can better understand the patients’ needs and continue to optimize health care. I look forward to working with the team as we continue to develop and expand our real-world evidence solutions in support of our global clients.”